ArticleOncology letters2026
LC-MS/MS-based clinical value exploration of the methionine cycle in luminal breast cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A group of patients with luminal breast cancer progresses to advanced stages because of endocrine therapy failure. While palbociclib improves the disease prognosis in the clinic, resistance after treatment remains a prominent issue. As a core systemic metabolic component, the methionine cycle currently lacks systematic research on luminal breast cancer and palbociclib resistance. The present study enrolled 146 patients with luminal breast cancer and 36 HCs from Jiangsu Cancer Hospital (Nanjing, China). Liquid chromatography-tandem mass spectrometry was used to detect the methionine cycle-related metabolites in the plasma. The Mann-Whitney U test was used to compare intergroup differences and diagnostic efficacy was evaluated using receiver operating characteristic curve analysis. Least absolute shrinkage and selection operator was applied to screen resistance-related variables, after which a nomogram prediction model was constructed. Plasma levels of methionine, S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH) and homocysteine were lower in patients with luminal breast cancer when compared with HCs, with an AUC of 0.8130 for the combined metabolites in diagnosis. Late-stage patients had lower methionine, SAM, SAH, as well as the SAM/SAH ratio than early-stage patients, with combined metabolites achieving an AUC of 0.9228. Additionally, palbociclib-resistant patients had lower SAM, SAH and homocysteine levels, with combined metabolites showing an AUC of 0.9229 for resistance identification. Finally, five variables were screened and used to construct a nomogram prediction model, with an AUC >0.9000 in the training set and 0.8000 in the internal validation sets. The present results suggest that methionine cycle-related metabolites are promising potential biomarkers for the diagnosis and progression assessment of luminal breast cancer. Furthermore, the constructed nomogram prediction model provides a new strategy for timely clinical treatment and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.